New Published Clinical Trial Results Confirm that PleuraFlow Enables Improved Quality and Cost of Care for Cardiac Surgery Patients

New Published Clinical Trial Results Confirm that PleuraFlow Enables Improved Quality and Cost of Care for Cardiac Surgery Patients Reduction of Patient Complications and Hospital Resource Utilization After Heart Surgery Demonstrated with Use of the PleuraFlow ACT System Irvine, CA – November 20, 2019 — ClearFlow, Inc., a medical device company based in Irvine, California, has announced positive clinical trial results published in the peer-reviewed Journal of Cardiothoracic Surgery. The trial evaluated the use of the PleuraFlow® Active Clearance Technology® (ACT®) System in prevention of retained blood complications in heart surgery patients. PleuraFlow is a medical device used at the bedside in the ICU that enables caregivers to proactively maintain

ClearFlow Announces Positive Randomized Controlled Trial Results and Inclusion in ERAS Guideline Recommendations

  ClearFlow Announces Positive Randomized Controlled Trial Results and Inclusion in ERAS Guideline Recommendations   Anaheim, California–May 7, 2019–ClearFlow, Inc., a medical device company based in Anaheim, California, has announced that positive clinical trial results of its PleuraFlow® device were presented at the American Association for Thoracic Surgery (AATS) 99th Annual meeting on May 4 in Toronto, Canada. This new data stems from a trial evaluating the use of ClearFlow’s PleuraFlow® Active Clearance Technology® (ACT®) System in heart surgery patients at the Montreal Heart Institute.   PleuraFlow is a medical device used at the bedside in the ICU that enables caregivers to actively maintain chest tube patency following cardiac surgery.

ERAS Cardiac Surgery Featured at Dedicated Session at European Association for Cardio-Thoracic Surgery in Milan

ERAS Cardiac Surgery Featured at Dedicated Session at European Association for Cardio-Thoracic Surgery in Milan   Springfield, MA — October 24, 2018 — The ERAS Cardiac Surgery Society presented its recent consensus statement at the 32nd European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting in Milan, Italy, last week as part of an educational session.   This dedicated ERAS Cardiac Surgery session was held during EACTS, the world’s largest cardiothoracic surgery focused professional conference with international speakers across all subspecialties.   ERAS Cardiac Surgery is a patient safety organization with the mission to facilitate optimization of perioperative care of cardiac surgical patients through collaborative discovery, analysis, expert consensus, and dissemination of best

ClearFlow Awarded Chest Drainage Products Agreement with Premier

ClearFlow Awarded Chest Drainage Products Agreement with Premier Anaheim, CA – August 21, 2018— ClearFlow, Inc., a medical device company based in Anaheim, California, announced today that it has been awarded a group purchasing agreement for the Chest Drainage Products category with Premier. Effective July 15th 2018, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for: –PleuraFlow Active Clearance Technology (ACT) System; –PleuraFlow Active Clearance Technology (ACT) System with FlowGlide “ClearFlow is proud to now be able to bring its Active Clearance Technology devices to Premier members under these new arrangements with one of the country’s leading GPOs,”

ClearFlow Announces Additional Positive US Clinical Trial Results at the 2018 NTI Critical Care Exposition

ClearFlow Announces Additional Positive US Clinical Trial Results at the 2018 NTI Critical Care Exposition Reduction of Hospital Complications and Resource Utilization after Heart Surgery Demonstrated with Use of the PleuraFlow® ACT® System.  Boston, MA – May 29th, 2018 — ClearFlow, Inc., a medical device company based in Anaheim, California, has announced that positive clinical trial results were presented at the National Teaching Institute (NTI) & Critical Care Exposition 2018 annual meeting on May 23rd, 2018 in Boston, MA.  The findings were presented by the study principal investigator, Dr. Yvon Baribeau, of Catholic Medical Center in Manchester, New Hampshire, in a presentation titled “Active Clearance of Chest Drains Reduces Pleural